Correlation between relative amounts of lipid species and number of days since the onset of symptoms among COVID-19 cases. by Spela Kokelj (8356644)

Subjects:

General characteristics and clinical data of the subjects included in the study. by Spela Kokelj (8356644)

Subjects:

Distribution of average relative amounts of lipid classes. by Spela Kokelj (8356644)

Subjects:

Flow chart on the inclusion and drop out of patients. by Spela Kokelj (8356644)

Subjects:

Differentially abundant lipid species in COVID-19 cases at baseline and at follow-up as compared to healthy controls. by Spela Kokelj (8356644)

Subjects:

Symptoms reported by COVID-19 cases at baseline and at follow-up. by Spela Kokelj (8356644)

Subjects:

Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. by Mohammad Bakhtiari (11838264)

Effects of BM-MSCs on ROS generation in DCS rats. by Chen Lu (135200)

Subjects:

Pretreatment of BM-MSCs attenuates DCS induced lung inflammation. by Chen Lu (135200)

Subjects:

Isotype control overlays. by Chen Lu (135200)

Subjects:

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Original uncropped blot. by Chen Lu (135200)

Subjects:

Characterization of BM-MSC. by Chen Lu (135200)

Subjects:

Pretreatment of BM-MSCs improves the survival rate and incidence of DCS. by Chen Lu (135200)

Subjects:

Utilization of anticoagulants at eight hospitals from 2019 to 2023. by Wei Luo (80175)

Subjects:

The ANCOVA and Post_hoc results. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

The demographical and clinical characteristics of subjects at baseline. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Identification of BM-MSCs. by Chen Lu (135200)

Subjects:

CONSORT flowchart. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Effect of BM-MSCs in improving DCS induced lung injury. by Chen Lu (135200)

Subjects: